

Efficacy and Safety of Once-Daily Vibegron in Older Adults with Overactive Bladder

Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Trial

NCT03492281

Overactive Bladder (OAB)

Overactive bladder (OAB) is prevalent among older adults (>45 years)¹.

Current drug treatments (anticholinergics) are rife with side-effects and are **not recommended**.

Vibegron (β 3-adrenergic agonist) was deemed safe and effective for OAB treatment (EMPOWUR)².



Does Vibegron treat OAB in geriatric adults?

Objective: assess the efficacy of daily 75 mg vibegron in treating OAB in geriatric adults (≥ 65 and ≥ 75 years).

12-week, randomized, double-blind, placebo- and active-control
(**4 mg tolterodine**).

Included geriatric adults (≥ 65 years) with at least 3 months of OAB.

Treatment groups are well-balanced


Primary endpoints: daily micturitions and urge urinary incontinence (UUI).

Secondary efficacy endpoints: daily urgency episodes.

Subgroup	Total	Vibegron	Placebo	Tolterodine
≥ 65 years	628	242	220	166
≥ 75 years	179	75	57	47

Adapted from Varano S et al., *Drugs & Aging*. 2021;38:137-146, under CC BY-NC 4.0 license.


Vibegron reduced daily micturitions by week 2



(LS) least-squares, * $P < 0.05$, *** $P < 0.001$

Adapted from Varano S et al., *Drugs & Aging*. 2021;38:137-146, under CC BY-NC 4.0 license.


Vibegron demonstrates similar efficacy with UUI



(LS) least-squares, ** $P < 0.01$, *** $P < 0.001$

Adapted from Varano S et al., *Drugs & Aging*. 2021;38:137-146, under CC BY-NC 4.0 license.


Urgency episodes were reduced across both age groups



(LS) least-squares, * $P < 0.05$, ** $P < 0.01$

Adapted from Varano S et al., *Drugs & Aging*. 2021;38:137-146, under CC BY-NC 4.0 license.

The safety profile is akin to the placebo and control



(TEAE) treatment-emergent adverse event

Adapted from Varano S *et al.*, *Drugs & Aging*. 2021;38:137-146, under CC BY-NC 4.0 license.

Key points and takeaways

- 1** Once-daily **75 mg vibegron** provides OAB relief improvements across both coprimary endpoints.
- 2** Treatment with vibegron also demonstrated improvement with secondary efficacy endpoints.
- 3** Vibegron's safety profile is consistent with the overall population and the placebo.

References

1. Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥ 65 and ≥ 75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. *Drugs and Aging*. 2021;38(2):137-146. doi:10.1007/S40266-020-00829-Z/TABLES/4
2. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. *The Journal of Urology*. 2020;204(2):316-323. doi:10.1097/JU.0000000000000807